関連ニュース

ImmuCell NASDAQ: ICCC reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 millio

PORTLAND, Maine, July 09, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets product